Key result
Selective thromboxane synthase inhibition improved one-week prosthetic graft patency to 81% compared with 46% in untreated dogs, comparable to conventional cyclooxygenase inhibition.
Why the study?
Does selective thromboxane synthase inhibition or cyclooxygenase inhibition improve arterial graft patency and reduce platelet deposition in dogs undergoing carotid artery replacement?
Population
35 mongrel dogs undergoing carotid artery replacement with 4 mm X 4 cm polytetrafluoroethylene and Dacron…
Comparison
Selective thromboxane synthase inhibition… vs Untreated control dogs
Design
Preclinical
Follow-up
1 week
Authors
Loading...
Should not change human graft management; leaves open translation of canine patency benefits to clinical arterial bypass.
Does selective thromboxane synthase inhibition or cyclooxygenase inhibition improve arterial graft patency and reduce platelet deposition in dogs undergoing carotid artery replacement?
Absolute Event Rate: 81% vs 46%
Selective thromboxane synthase inhibition improves small-caliber prosthetic graft patency to a similar extent as conventional cyclooxygenase inhibition in a canine model.
Martha D. McDaniel (1987) studied carotid artery replacement (n=35). Thromboxane synthase inhibition (U-63557A) vs. Untreated control was evaluated on One-week graft patency. Selective thromboxane synthase inhibition improved one-week prosthetic graft patency to 81% compared with 46% in untreated dogs, comparable to conventional cyclooxygenase inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: